Hepatitis C in the rituximab era

Slides:



Advertisements
Similar presentations
Hepatitis C for the General Practitioner Morris Sherman MB BCh PhD FRCP(C) University of Toronto January 2013.
Advertisements

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.
Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus–related mixed cryoglobulinemia: a long-term study by Franco Dammacco,
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Where Are We on the Path to Elimination of Chronic Hepatitis C?
The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection by.
R. Cavallo  Clinical Microbiology and Infection 
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.
Volume 66, Issue 3, Pages (March 2017)
by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa
Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.
by James O. Armitage, and Dan L. Longo
Chronic Hepatitis C Therapy: Changing the Rules of Duration
Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.
Number of HCV tests conducted
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Rituximab-induced tumor cell agglutination
Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.
How I treat elderly patients with myeloma
Nonmyeloablative conditioning for relapsed follicular lymphoma
More Than Treatment.
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma by Chan Yoon Cheah, Loretta J. Nastoupil,
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.
Coiffier B et al. Proc ASH 2010;Abstract 857.
J. Ambrosioni, A. Mamin, A. Hadengue, M. Bernimoulin, K. Samii, C
Relapsed lymphoma preceded by cold agglutinin disease
Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study by Dirk.
High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.
Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,
Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.
Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.
Stage C or not stage C…? by Claire Dearden Blood
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Blocking VWF platelet binding to treat TTP
by Michael F. Leahy, and J. Harvey Turner
by Jon E. Arnason, Federico Campigotto, Donna Neuberg, and James B
Latest lymphoma classification is skin deep
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience by Daryl Tan, Sandra.
Stephen Ansell, MD, PhD Mayo Clinic
How I treat refractory CLL
Volume 125, Issue 6, Pages (December 2003)
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Volume 63, Issue 6, Pages (June 2003)
Yasuhiko Sugawara, Masatoshi Makuuchi 
Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents  Andreas Kyvernitakis,
by Alex C. Spyropoulos, and James D. Douketis
The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review  Denise M.
A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen- positive patients: a prospective cohort study in China  Y. Zhang,
A Guideline-Based Approach to HCV Care
New HCV therapies on the horizon
Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
Volume 142, Issue 6, Pages (May 2012)
Cytomegalovirus Reactivation Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Chemotherapeutics.
Chronic Hepatitis C Therapy: Changing the Rules of Duration
Factors related to the chronicity and evolution of hepatitis C infection in patients co- infected by the human immunodeficiency virus  R. Pérez-Cano, C.
Sharon J. Hutchinson, Sheila M. Bird, David J. Goldberg 
Superiority of Obinutuzumab over Rituximab in a New Molecular Follicular Lymphoma-like Subgroup of DLBCL: Results from an Exploratory Analysis of the Phase.
Clinical Gastroenterology and Hepatology
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas by Erin G. Reid, David Looney,
by Wendy Lim, Sara K. Vesely, and James N. George
An algorithmic approach to FL
Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma.
How I treat heparin-induced thrombocytopenia and thrombosis
How I treat early-relapsing follicular lymphoma
by Lapo Alinari, and Kristie A. Blum
Initial treatment of CLL: integrating biology and functional status
Optimizing therapy for nodal marginal zone lymphoma
Presentation transcript:

Hepatitis C in the rituximab era by James M. Foran Blood Volume 116(24):5081-5082 December 9, 2010 ©2010 by American Society of Hematology

Grade III elevation of transaminases following 6 cycles of R-CHOP for advanced grade III follicular lymphoma in a patient treated at the University of Alabama at Birmingham with chronic HCV infection and elevated HCV viral load (> 107 copies/mL). Grade III elevation of transaminases following 6 cycles of R-CHOP for advanced grade III follicular lymphoma in a patient treated at the University of Alabama at Birmingham with chronic HCV infection and elevated HCV viral load (> 107 copies/mL). The albumin and bilirubin remained normal throughout therapy. The patient did not receive further antiviral therapy and the transaminases normalized after approximately 2 years. James M. Foran Blood 2010;116:5081-5082 ©2010 by American Society of Hematology